(Q38763826)

6 September 2017

title

Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin (English)

1 reference

6 September 2017

Yu-Chien Chang

1

1 reference

6 September 2017

Wen-Jyi Lo

2

1 reference

6 September 2017

Yu-Ting Huang

3

1 reference

6 September 2017

Chaio-Lin Lin

4

1 reference

6 September 2017

Chiu-Che Feng

5

1 reference

6 September 2017

Hsin-Ting Lin

6

1 reference

6 September 2017

Hsu-Chen Cheng

7

1 reference

6 September 2017

Su-Peng Yeh

8

1 reference

6 September 2017

publication date

31 January 2017

1 reference

6 September 2017

1 reference

6 September 2017

volume

58

1 reference

6 September 2017

issue

9

1 reference

6 September 2017

page(s)

1-12

1 reference

The role of iron and reactive oxygen species in cell death

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Body iron stores and the risk of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

HFE C282Y homozygotes are at increased risk of breast and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Role of iron in carcinogenesis: cancer as a ferrotoxic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Iron depletion results in Src kinase inhibition with associated cell cycle arrest in neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Flow cytometry measurement of the labile iron pool in human hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Genetic factors influencing cytarabine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

Recombinant human cytidine deaminase: expression, purification, and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1280604

10.1080/10428194.2017.1280604

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference